Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy

Abdourahman Cham,1,2 Mayank Bansal,3 Himanshu K Banda,4 Young Kwon,1 Paul S Tlucek,1 Alexander G Bassuk,5 Stephen H Tsang,6,7 Warren M Sobol,8 James C Folk,1 Steven Yeh,4 Vinit B Mahajan1,2 1Department of Ophthalmology and Visual Sciences, 2Omics Laboratory, University of Iowa, Iowa City, IA, USA;...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cham A, Bansal M, Banda HK, Kwon Y, Tlucek PS, Bassuk AG, Tsang SH, Sobol WM, Folk JC, Yeh S, Mahajan VB
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	ADNIV CAPN5 calpain-5 Fluocinolone Acetonide Secondary Glaucoma Uveitis. Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/0a9207be1b6a43b7b334aaf7a0e786d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0a9207be1b6a43b7b334aaf7a0e786d8
record_format	dspace
spelling	oai:doaj.org-article:0a9207be1b6a43b7b334aaf7a0e786d82021-12-02T02:17:02ZSecondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy1177-5483https://doaj.org/article/0a9207be1b6a43b7b334aaf7a0e786d82016-06-01T00:00:00Zhttps://www.dovepress.com/secondary-glaucoma-in-capn5-associated-neovascular-inflammatory-vitreo-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Abdourahman Cham,1,2 Mayank Bansal,3 Himanshu K Banda,4 Young Kwon,1 Paul S Tlucek,1 Alexander G Bassuk,5 Stephen H Tsang,6,7 Warren M Sobol,8 James C Folk,1 Steven Yeh,4 Vinit B Mahajan1,2 1Department of Ophthalmology and Visual Sciences, 2Omics Laboratory, University of Iowa, Iowa City, IA, USA; 3Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India; 4Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, 5Department of Pediatrics, University of Iowa, Iowa City, IA, 6Barbara and Donald Jonas Laboratory of Stem Cells and Regenerative Medicine and Bernard and Shirlee Brown Glaucoma Laboratory, Department of Pathology and Cell Biology, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University, 7Edward S Harkness Eye Institute, New York-Presbyterian Hospital, New York, NY, 8Retina Physicians & Surgeons, Inc., Dayton, OH, USA Objective: The objective of this study was to review the treatment outcomes of patients with secondary glaucoma in cases of autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV), a hereditary autoimmune uveitis due to mutations in CAPN5. Patients and methods: A retrospective, observational case series was assembled from ADNIV patients with secondary glaucoma. The main outcome measures were intraocular pressure (IOP), visual acuity, use of antiglaucoma medications, ocular surgeries, and adverse outcomes. Perimetry and optic disk optical coherence tomography (OCT) were also analyzed. Results: Nine eyes of five ADNIV patients with secondary glaucoma were reviewed. Each received a fluocinolone acetonide (FA) implant for the management of posterior uveitis. Following implantation, no eyes developed neovascular glaucoma. Five eyes (in patients 1, 2, and 5) required Ahmed glaucoma valve surgery for the management of steroid-responsive glaucoma. Patient 2 also developed angle closure with iris bombe and underwent laser peripheral iridotomy. Patient 4 had both hypotony and elevated IOP that required periodic antiglaucoma medication in the FA-implanted eye. Patient 3 did not develop steroid-response glaucoma in either eye. Optic disk examinations were obscured by fibrosis and better assessed with OCT. Conclusion: ADNIV patients show combined mechanism secondary glaucoma best assessed by OCT of the optic disk. The FA implants have reduced uveitic and neovascular glaucoma. Nevertheless, IOP management remains complex due to steroid-response glaucoma, angle closure glaucoma, and hypotony. Keywords: ADNIV, CAPN5, calpain-5, fluocinolone acetonide, secondary glaucoma, uveitisCham ABansal MBanda HKKwon YTlucek PSBassuk AGTsang SHSobol WMFolk JCYeh SMahajan VBDove Medical PressarticleADNIVCAPN5calpain-5Fluocinolone AcetonideSecondary GlaucomaUveitis.OphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 1187-1197 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	ADNIV CAPN5 calpain-5 Fluocinolone Acetonide Secondary Glaucoma Uveitis. Ophthalmology RE1-994
spellingShingle	ADNIV CAPN5 calpain-5 Fluocinolone Acetonide Secondary Glaucoma Uveitis. Ophthalmology RE1-994 Cham A Bansal M Banda HK Kwon Y Tlucek PS Bassuk AG Tsang SH Sobol WM Folk JC Yeh S Mahajan VB Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy
description	Abdourahman Cham,1,2 Mayank Bansal,3 Himanshu K Banda,4 Young Kwon,1 Paul S Tlucek,1 Alexander G Bassuk,5 Stephen H Tsang,6,7 Warren M Sobol,8 James C Folk,1 Steven Yeh,4 Vinit B Mahajan1,2 1Department of Ophthalmology and Visual Sciences, 2Omics Laboratory, University of Iowa, Iowa City, IA, USA; 3Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India; 4Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, 5Department of Pediatrics, University of Iowa, Iowa City, IA, 6Barbara and Donald Jonas Laboratory of Stem Cells and Regenerative Medicine and Bernard and Shirlee Brown Glaucoma Laboratory, Department of Pathology and Cell Biology, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University, 7Edward S Harkness Eye Institute, New York-Presbyterian Hospital, New York, NY, 8Retina Physicians & Surgeons, Inc., Dayton, OH, USA Objective: The objective of this study was to review the treatment outcomes of patients with secondary glaucoma in cases of autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV), a hereditary autoimmune uveitis due to mutations in CAPN5. Patients and methods: A retrospective, observational case series was assembled from ADNIV patients with secondary glaucoma. The main outcome measures were intraocular pressure (IOP), visual acuity, use of antiglaucoma medications, ocular surgeries, and adverse outcomes. Perimetry and optic disk optical coherence tomography (OCT) were also analyzed. Results: Nine eyes of five ADNIV patients with secondary glaucoma were reviewed. Each received a fluocinolone acetonide (FA) implant for the management of posterior uveitis. Following implantation, no eyes developed neovascular glaucoma. Five eyes (in patients 1, 2, and 5) required Ahmed glaucoma valve surgery for the management of steroid-responsive glaucoma. Patient 2 also developed angle closure with iris bombe and underwent laser peripheral iridotomy. Patient 4 had both hypotony and elevated IOP that required periodic antiglaucoma medication in the FA-implanted eye. Patient 3 did not develop steroid-response glaucoma in either eye. Optic disk examinations were obscured by fibrosis and better assessed with OCT. Conclusion: ADNIV patients show combined mechanism secondary glaucoma best assessed by OCT of the optic disk. The FA implants have reduced uveitic and neovascular glaucoma. Nevertheless, IOP management remains complex due to steroid-response glaucoma, angle closure glaucoma, and hypotony. Keywords: ADNIV, CAPN5, calpain-5, fluocinolone acetonide, secondary glaucoma, uveitis
format	article
author	Cham A Bansal M Banda HK Kwon Y Tlucek PS Bassuk AG Tsang SH Sobol WM Folk JC Yeh S Mahajan VB
author_facet	Cham A Bansal M Banda HK Kwon Y Tlucek PS Bassuk AG Tsang SH Sobol WM Folk JC Yeh S Mahajan VB
author_sort	Cham A
title	Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy
title_short	Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy
title_full	Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy
title_fullStr	Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy
title_full_unstemmed	Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy
title_sort	secondary glaucoma in capn5-associated neovascular inflammatory vitreoretinopathy
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/0a9207be1b6a43b7b334aaf7a0e786d8
work_keys_str_mv	AT chama secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy AT bansalm secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy AT bandahk secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy AT kwony secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy AT tlucekps secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy AT bassukag secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy AT tsangsh secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy AT sobolwm secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy AT folkjc secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy AT yehs secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy AT mahajanvb secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy
_version_	1718402571349000192

Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy

Ejemplares similares